These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7535458)

  • 1. High-dose therapy and growth factor mobilized peripheral blood progenitor cell support for responding patients with metastatic breast cancer.
    Stadtmauer EA; Hodi FS; Sickles C; Biggs DD; Mangan P; Buzby G; Zaleta E; Silberstein L
    Prog Clin Biol Res; 1994; 389():487-95. PubMed ID: 7535458
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
    Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF
    Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
    Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
    Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large volume leukapheresis following peripheral blood stem cell mobilization by cyclophosphamide and granulocyte-macrophage colony stimulating factor.
    Safran H; Caguioa P; Tansan S
    Prog Clin Biol Res; 1994; 389():639-42. PubMed ID: 7700930
    [No Abstract]   [Full Text] [Related]  

  • 5. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting the mobilization of primitive and committed hematopoietic progenitors into the peripheral blood of cancer patients.
    Schneider JG; Crown JP; Wasserheit C; Kritz A; Wong G; Reich L; Norton L; Moore MA
    Bone Marrow Transplant; 1994 Dec; 14(6):877-84. PubMed ID: 7536069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative assessment of colony growth and hematologic engraftment in patients undergoing high-dose chemotherapy and autologous bone marrow transplantation for breast cancer.
    Meehan KR; Ericson SG; Tosteson TD; Mills LE
    Prog Clin Biol Res; 1994; 389():497-503. PubMed ID: 7535459
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy.
    Mohr M; Hilgenfeld E; Fietz T; Hoppe B; Koenigsmann M; Hoffmann M; Knauf WU; Cassens U; Sibrowski W; Kienast J; Thiel E; Berdel WE
    Clin Cancer Res; 1999 May; 5(5):1035-40. PubMed ID: 10353736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
    Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL
    Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
    deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
    Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy.
    Zimmerman TM; Mick R; Myers S; Bender JG; Lee WJ; Williams SF
    Bone Marrow Transplant; 1995 Jun; 15(6):923-7. PubMed ID: 7581092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
    Meisenberg BR; Miller WE; McMillan R
    Bone Marrow Transplant; 1996 Dec; 18(6):1087-93. PubMed ID: 8971377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
    Vahdat LT; Balmaceda C; Papadopoulos K; Frederick D; Donovan D; Sharpe E; Kaufman E; Savage D; Tiersten A; Nichols G; Haythe J; Troxel A; Antman K; Hesdorffer CS
    Bone Marrow Transplant; 2002 Aug; 30(3):149-55. PubMed ID: 12189532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of three mobilization regimens for peripheral blood progenitor cell rescue after high dose chemotherapy.
    Lee WJ; Zimmerman T; Meyers S; Bender JG; Williams SF
    Prog Clin Biol Res; 1994; 389():421-7. PubMed ID: 7535451
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined therapy with rG-CSF and GM-CSF for the mobilization of hematopoietic progenitor cells.
    Winter JN; Mangan C; Bryd K; Tallman M; Gordon L; Jahnke L; Lazarus H; Cooper B; Crum E; Horvath N
    Prog Clin Biol Res; 1994; 389():463-70. PubMed ID: 7535455
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
    Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
    Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-intensity chemotherapy with peripheral blood progenitor cell support.
    Fennelly D; Vahdat L; Schneider J; Reich L; Hamilton N; Hakes T; Raptis G; Wasserheit C; Kritz A; Gulati S
    Semin Oncol; 1994 Apr; 21(2 Suppl 2):21-5; quiz 26, 58. PubMed ID: 7515513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
    Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.